Trial of Imatinib for Hospitalized Adults With COVID-19

Clinical Trial ID NCT04394416

PubWeight™ 0.00‹?›

🔗 Visit the page for NCT04394416

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 18.32
2 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020 10.90
3 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
4 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 4.49
5 Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003 2.23
6 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 2.03
7 In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004 1.42
8 Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011 1.40
9 The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005 1.23
10 Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003 1.19
11 Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem 2014 1.05
12 Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 2009 1.03
13 ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 2009 0.95
14 Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2015 0.95
15 Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015 0.89
16 Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993 0.85
17 Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr) 2015 0.84
18 Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2012 0.84
19 Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006 0.82
20 The contribution of lysosomal trapping in the uptake of desipramine and chloroquine by different tissues. Pharmacol Toxicol 1995 0.81
21 Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2015 0.81
22 Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. PLoS One 2014 0.80
23 Lysosomal Sequestration Determines Intracellular Imatinib Levels. Mol Pharmacol 2015 0.78
24 Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes. Int J Pharm Compd 2017 0.75
25 Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib. Exp Lung Res 2015 0.75
26 Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 1988 0.75
Next 100